CN1413203A - 制备4-(杂芳基-甲基)-卤素-1(2h)-2,3-二氮杂萘酮的方法 - Google Patents

制备4-(杂芳基-甲基)-卤素-1(2h)-2,3-二氮杂萘酮的方法 Download PDF

Info

Publication number
CN1413203A
CN1413203A CN00817560A CN00817560A CN1413203A CN 1413203 A CN1413203 A CN 1413203A CN 00817560 A CN00817560 A CN 00817560A CN 00817560 A CN00817560 A CN 00817560A CN 1413203 A CN1413203 A CN 1413203A
Authority
CN
China
Prior art keywords
reaction
methyl
halogen
heteroaryl
pyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN00817560A
Other languages
English (en)
Other versions
CN1221545C (zh
Inventor
奥林·彼得罗夫
托马斯·海纳
哈瑞波特·内赫
马丁·克鲁格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Publication of CN1413203A publication Critical patent/CN1413203A/zh
Application granted granted Critical
Publication of CN1221545C publication Critical patent/CN1221545C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Catalysts (AREA)

Abstract

本发明涉及4-(杂芳基-甲基)-卤素-1(2H)-2,3-二氮杂萘酮、特别是4-(4-吡啶基甲基)-1(2H)-2,3-二氮杂萘酮的制备方法,其特征在于2-苯并[c]呋喃酮基-3-三苯基磷盐在碱性助剂的存在下与4-吡啶醛反应,随后与肼反应,然后进行酸处理。该方法避免了已知方法中的技术问题、安全问题、以及环境问题。

Description

制备4-(杂芳基-甲基)-卤素-1(2H)-2,3-二氮杂 萘酮的方法
技术领域
本发明涉及制备4-(杂芳基-甲基)-卤素-1(2H)-2,3-二氮杂萘酮的方法。
背景技术
4-(杂芳基-甲基)-卤素-1(2H)-2,3-二氮杂萘酮,特别是4-(4-吡啶基甲基)-1(2H)-2,3-二氮杂萘酮,在制备2,3-二氮杂萘衍生物中是特别有价值的中间产物,而2,3-二氮杂萘衍生物的特征是具有有利的药理性质如抑制血管生成(WO 98/35958)、抑制cGMP磷酸二酯酶(EP 0 722 936)、抑制炎症和抗高血压作用(DE OS 2 021195),并由此提供了新的治疗可能性,特别是对于治疗癌症及心脏病。
根据已知的方法,制备例如4-(4-吡啶基甲基)-1(2H)-2,3-二氮杂萘酮是如下进行的:在约20℃下使邻苯二甲酸酐与4-甲基吡啶反应,然后再使得到的缩合产物(γ-pyrophthalone)与过量的肼在130℃下反应(DE AS 1 061 788)。这些方法的缺陷是产率低(<50%),产品质量差,而且主要是缩合反应要求非常高的温度,这使得难以应用于工业规模的生成中。
作为另一个替代方法,4-(4-吡啶基甲基)-1(2H)-2,3-二氮杂萘酮可如下制备:使2-苯并[c]呋喃酮与4-吡啶醛在甲醇存在下进行缩合,然后再使得到的2-(4(1H)-pvridinylidene)-4,5,6,7-四氢茚-1,3-二酮与大大过量(16当量)的肼在130℃下反应(WO 98/35958)。两步的总产率约为理论值的40%。在这些方法中,在高于肼的分解温度(约120℃)的温度下处理过量的致癌性肼,其本身就是-个非常严重的问题。在此情况下,在产物的处理和分离中使肼在空气(MAK 0.008ppm)和废水中维持非常低的界限值几乎是不可能的。
然而,由WO 99/32456中可知道其中肼过量约100倍而且反应温度接近于肼分解温度(约120℃)的反应。在工业规模上,此等方法本身就是非常成问题的。而且产率相对也低。
因此,希望得到4-(杂芳基-甲基)-卤素-1(2H)-2,3-二氮杂萘酮、特别是4-(4-吡啶基甲基)-1(2H)-2,3-二氮杂萘酮可行的制备方法,其可避免已知方法中的技术问题(在200℃下反应)、安全问题(将肼加热至130℃)、以及环境问题(大大过量的肼)。
现在,这些已知的缺陷可用本发明的方法来克服。
发明内容
本发明的目的是提供制备通式I之4-(杂芳基-甲基)-卤素-1(2H)-2,3-二氮杂萘酮的方法,其中:R1=氟、氯、溴或氢,而Ar=吡啶、吡嗪或者嘧啶基,
所述方法的特征在于,通式II之经取代的2-苯并[c]呋喃酮基-3-三苯基磷盐
Figure A0081756000061
其中:R1=氟、氯、溴或氢,在碱存在下与通式III之醛反应,
Ar-CHO    III
其中:Ar=吡啶、吡嗪或者嘧啶基,然后与水合肼反应,并任选在酸性条件下处理。
具体实施方式
如果基团R1代表卤素,则可在吡嗪酮系统中的苯基环的任意位置上,也就是说在1-、2-、3-、或4-位。对于合适的Ar基团,可以是吡啶、嘧啶或者吡嗪基。合适的醛例如是2-、3-、或4-吡啶-醛,2-甲基-4-吡啶-醛,3-甲基-4-吡啶-醛,4-嘧啶-醛,5-嘧啶醛,3-吡嗪-醛或者4-吡嗪-醛。
因此,例如2-苯并[c]呋喃酮基-3-三苯基磷盐与4-吡啶醛在碱(碱性助剂)存在下反应,随后与水合肼反应,然后对反应混合物进行酸处理。具体而言是如下实现的:2-苯并[c]呋喃酮基-3-三苯基磷盐与4-吡啶醛在碱(碱性助剂)存在下于溶剂中反应,然后与1-1.1当量的水合肼反应,接着再用0.1-0.3当量的乙酸酐对反应混合物进行处理。
为分离产物,反应混合物与含水酸混合,蒸馏掉溶剂,过滤出沉淀的三苯基膦,然后使滤液碱化。在此情况下,沉淀出所希望的产物,而且在过滤和干燥后具有非常高的纯度和优异的产率(理论值的95-98%)。
对于反应中的溶剂,有机溶剂是合适的,例如四氢呋喃、二甲氧基乙烷、甲醇、乙醇或者二甲基甲酰胺。可使用的碱是有机碱,如胺,例如三乙胺、乙基二异丙基胺,或者是无机碱,如碳酸钾、碳酸钠、碳酸镁、或者氢氧化镁。2-苯并[c]呋喃酮基-3-三苯基磷盐反应时的反应时间在40℃下为1小时,而与肼的反应则是在50-70℃下7-14小时。
用作离析物的2-苯并[c]呋喃酮基-3-三苯基磷盐(溴化物和氯化物)可根据文献中已知的方法容易地得到(J.Organometallic Chem.1972,391;J.Org.Chem.1973,4164)。
与现有技术中已知的方法相比,根据本发明的方法的优点在于反应条件不苛刻,显著更高的产率(>90%),而且特别是可以使用化学计量量的肼。反应进行完全,而且在封闭的系统中,使得在处理之前,在反应混合物中没有检测出肼(单点反应)。因此,可以避免肼的致癌危险。
实施例制备4-(4-吡啶基甲基)-2,3-二氮杂萘酮
将500g的2-苯并[c]呋喃酮基-3-三苯基氯化磷(1.160mol)悬浮在225ml的四氢呋喃(THF)中。在5℃下,添加110.7ml的吡啶-4-醛(124.2g,1.160mol),然后在白色的悬浮液中计量加入161.7ml的三乙胺(117.4g,1.160mol)。添加完成后,在40℃下搅拌反应混合物1小时,然后与62.0ml的水合肼(63.9 g,1.276mol)混合,并在70℃下搅拌8小时。接着加入32.7ml的乙酸酐(35.5g,0.348mol),并在20℃下继续搅拌2.5小时。反应混合物接着先与1500ml的水混合,然后与367ml的4M硫酸溶液混合。在真空中由该反应液中蒸馏出约2500ml的THF/水。使所得的悬浮液由玻璃料中过滤。滤液与50%的氢氧化钠溶液混合,直至pH为8.0(约185ml)。过滤出所沉淀的产物,用450ml的水洗涤,然后在60℃下干燥。得到264.2g的淡黄色固体(理论值的96%)。
熔点:193-194℃。EI-MS(M+H)+242。
可类似于本实施例制备其他衍生物。

Claims (4)

1、制备通式I之4-(杂芳基-甲基)-卤素-1(2H)-2,3-二氮杂萘酮的方法,其中:R1=氟、氯、溴或氢,而Ar=吡啶、吡嗪或者嘧啶基,
所述方法的特征在于,通式II之经取代的2-苯并[c]呋喃酮基-3-三苯基磷盐
Figure A0081756000022
其中:R1=氟、氯、溴或氢,在碱存在下与通式III之醛反应,
Ar-CHO    III
其中:Ar=吡啶、吡嗪或者嘧啶基,然后与水合肼反应,并任选在酸性条件下进行处理。
2、如权利要求1所述的方法,其中所述碱是胺或者碱金属氢氧化物或者碱土金属氢氧化物。
3、如权利要求1所述的方法,其中与水合肼反应,而且反应混合物随后用乙酸酐或者乙酸进行处理。
4、如权利要求1所述的方法,其中与1-1.1当量的水合肼反应,而且反应混合物随后用0.1-0.3当量的乙酸酐进行处理。
CNB008175608A 1999-12-23 2000-12-20 制备4-(杂芳基-甲基)-卤素-1(2h)-2,3-二氮杂萘酮的方法 Expired - Fee Related CN1221545C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19963607A DE19963607B4 (de) 1999-12-23 1999-12-23 Verfahren zur Herstellung von 4-(Heteroaryl-methyl) halogen-1(2H)-phthalazinonen
DE19963607.9 1999-12-23

Publications (2)

Publication Number Publication Date
CN1413203A true CN1413203A (zh) 2003-04-23
CN1221545C CN1221545C (zh) 2005-10-05

Family

ID=7934888

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB008175608A Expired - Fee Related CN1221545C (zh) 1999-12-23 2000-12-20 制备4-(杂芳基-甲基)-卤素-1(2h)-2,3-二氮杂萘酮的方法

Country Status (32)

Country Link
US (1) US6891041B2 (zh)
EP (1) EP1242405B1 (zh)
JP (1) JP2003529555A (zh)
KR (1) KR100654265B1 (zh)
CN (1) CN1221545C (zh)
AT (1) ATE273972T1 (zh)
AU (1) AU772981B2 (zh)
BG (1) BG65387B1 (zh)
BR (1) BR0016634A (zh)
CA (1) CA2395407C (zh)
CZ (1) CZ20022146A3 (zh)
DE (2) DE19963607B4 (zh)
DK (1) DK1242405T3 (zh)
EE (1) EE04940B1 (zh)
ES (1) ES2223626T3 (zh)
HK (1) HK1055296A1 (zh)
HR (1) HRP20020605B1 (zh)
HU (1) HUP0300992A3 (zh)
IL (2) IL150017A0 (zh)
MX (1) MXPA02006224A (zh)
NO (1) NO321357B1 (zh)
NZ (1) NZ519285A (zh)
PL (1) PL200714B1 (zh)
PT (1) PT1242405E (zh)
RO (1) RO121211B1 (zh)
RS (1) RS50458B (zh)
RU (1) RU2250900C2 (zh)
SI (1) SI1242405T1 (zh)
SK (1) SK285522B6 (zh)
UA (1) UA72021C2 (zh)
WO (1) WO2001047912A1 (zh)
ZA (1) ZA200205853B (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1296984B1 (it) * 1997-12-19 1999-08-03 Zambon Spa Derivati ftalazinici inibitori della fosfodiesterasi 4
US7151102B2 (en) * 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB0419072D0 (en) * 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
UY30639A1 (es) * 2006-10-17 2008-05-31 Kudos Pharm Ltd Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
CA2702429A1 (en) * 2007-10-17 2009-04-23 Kudos Pharmaceuticals Limited Crystalline form l 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-phthalazin-1-one
EA020783B1 (ru) 2008-10-07 2015-01-30 Астразенека Юк Лимитед Фармацевтическая композиция, содержащая 4-[3-(4-циклопропанкарбонилпиперазин-1-карбонил)-4-фторбензил]-2н-фталазин-1-он и коповидон
US9783529B2 (en) 2013-03-13 2017-10-10 Flatley Discovery Lab, Llc Pyridazinone compounds and methods for the treatment of cystic fibrosis
CA2980028A1 (en) * 2015-03-19 2016-09-22 Clariant International Ltd Biodegradable sugar-amide-surfactants for enhanced oil recovery

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE567431A (zh) * 1957-05-07
GB1293565A (en) * 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
IE47592B1 (en) * 1977-12-29 1984-05-02 Ici Ltd Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
EP0634404A1 (en) * 1993-07-13 1995-01-18 Rhone Poulenc Agriculture Ltd. Phtalazin derivatives and their use as pesticides
HU219864B (hu) * 1994-08-09 2001-08-28 Eisai Co., Ltd. cGMP-PDE inhibitor kondenzált piridazinszármazékok és alkalmazásuk
JP3919835B2 (ja) * 1994-08-09 2007-05-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 縮合ピリダジン系化合物
AU5614198A (en) * 1996-12-18 1998-07-15 Neurogen Corporation Isoquinolinamine and phthalazinamine derivatives which interact with crf receptors
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
IT1296984B1 (it) * 1997-12-19 1999-08-03 Zambon Spa Derivati ftalazinici inibitori della fosfodiesterasi 4
ITMI981670A1 (it) * 1998-07-21 2000-01-21 Zambon Spa Derivati ftalazinici inibitori della fosfodiesterasi 4
ITMI981671A1 (it) * 1998-07-21 2000-01-21 Zambon Spa Derivati ftalazinici inibitori della fosfodisterasi 4
ITMI20000261A1 (it) * 2000-02-16 2001-08-16 Zambon Group Processo per la preparazione di piridiniliden-ftalidi

Also Published As

Publication number Publication date
YU47302A (sh) 2005-06-10
JP2003529555A (ja) 2003-10-07
NO20023014D0 (no) 2002-06-21
BG65387B1 (bg) 2008-05-30
CA2395407A1 (en) 2001-07-05
PL355525A1 (en) 2004-05-04
PL200714B1 (pl) 2009-01-30
EP1242405A1 (de) 2002-09-25
US6891041B2 (en) 2005-05-10
DE19963607B4 (de) 2005-12-15
HUP0300992A3 (en) 2005-11-28
CZ20022146A3 (cs) 2002-09-11
DE50007520D1 (de) 2004-09-23
RU2250900C2 (ru) 2005-04-27
NZ519285A (en) 2004-12-24
SK285522B6 (sk) 2007-03-01
HK1055296A1 (en) 2004-01-02
KR100654265B1 (ko) 2006-12-07
PT1242405E (pt) 2004-11-30
EE04940B1 (et) 2007-12-17
BG106843A (en) 2003-02-28
BR0016634A (pt) 2002-10-15
NO321357B1 (no) 2006-05-02
CA2395407C (en) 2009-04-28
KR20020062363A (ko) 2002-07-25
IL150017A (en) 2006-12-31
RS50458B (sr) 2010-03-02
MXPA02006224A (es) 2002-12-05
DK1242405T3 (da) 2004-11-01
AU2012201A (en) 2001-07-09
ES2223626T3 (es) 2005-03-01
HUP0300992A2 (hu) 2003-08-28
DE19963607A1 (de) 2001-07-12
IL150017A0 (en) 2002-12-01
ATE273972T1 (de) 2004-09-15
RO121211B1 (ro) 2007-01-30
ZA200205853B (en) 2004-02-18
HRP20020605A2 (en) 2004-12-31
AU772981B2 (en) 2004-05-13
EE200200307A (et) 2003-06-16
NO20023014L (no) 2002-06-21
SK8922002A3 (en) 2002-11-06
CN1221545C (zh) 2005-10-05
US20040192695A1 (en) 2004-09-30
WO2001047912A1 (de) 2001-07-05
HRP20020605B1 (en) 2007-06-30
UA72021C2 (en) 2005-01-17
RU2002119559A (ru) 2004-01-10
EP1242405B1 (de) 2004-08-18
SI1242405T1 (en) 2005-02-28

Similar Documents

Publication Publication Date Title
EP0274379B1 (en) Process for preparing pyridine-2,3-dicarboxylic acid compounds
CN101528700B (zh) 用于制备伊马替尼的方法及其中间体
DE60025803T2 (de) Herstellung von sulfonamiden
CN1221545C (zh) 制备4-(杂芳基-甲基)-卤素-1(2h)-2,3-二氮杂萘酮的方法
SA95150619B1 (ar) تحضير مركبات بورين purines
KR102684954B1 (ko) 아미노피리미딘 유도체의 합성에 유용한 신규의 중간체, 이의 제조방법 및 이를 이용한 아미노피리미딘 유도체의 제조방법
CN101508678B (zh) 2-甲基-4-氨基-5-乙酰氨甲基嘧啶的制备工艺方法
US4985563A (en) Process for the preparation of 6-piperidino-2,4-diamino pyrimidine-3-oxide
KR101471047B1 (ko) 고순도 보센탄의 개선된 제조방법
EP1046635A1 (en) Process for preparing an aromatic compound substituted by a tertiary nitrile
US4785113A (en) 2,4-dichloro-3,5,6-trimethylpyridine
CN115677707B (zh) 二氨基马来腈法制备2,4,6,8-四羟基嘧啶并[5,4-d]嘧啶的方法
KR920001564B1 (ko) 테트라하이드로이소퀴놀린 유도체
CN110386892B (zh) 一种4-氟-5-羟基-2-甲基-1h-吲哚的制备方法
KR100371087B1 (ko) 2-아세틸니코티닉산의 제조방법
CN117229216A (zh) 一种恩赛特韦中间体的制备方法
CN117126108A (zh) 一种Ensitrelvir中间体的制备方法
JP2005170848A (ja) 2,3−ジアミノピリジン類の製造方法
US20070265447A1 (en) Process for the Preparation of Ziprasidone (5-[2-[4-(1,2-Benziosothiazol-3-Y1)-1-Piperazinyl]Ethyl]-6-Chloro-1,3-Dihydro-2H-Indol-2- One
CN108947947A (zh) 一种沃拉帕沙中间体的制备方法
CN100348581C (zh) 烷氧基烟酸的制备方法
EP0086438A1 (en) Process and intermediates for preparing 4-hydroxymethyl-1-phthalazone derivatives
JP2003518002A (ja) 1−(6−メチルピリジン−3−イル)−2−[4−(メチルスルホニル)フェニル]エタノンおよびその製造方法
KR20010035293A (ko) 2,6-디클로로-5-플루오로 니코틴산 유도체의 제조방법
JPH05202053A (ja) ピリミドプテリジン誘導体及びその製造方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20051005

Termination date: 20100120